Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levodopa. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 6/20 | 0.77 |
| ▸ | USP2 | O75604 | 3/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.77 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.77 |
| ▸ | RECQL | P46063 | 2/20 | 0.77 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.77 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.77 |
| ▸ | EGFR | P00533 | 1/20 | 0.77 |
| ▸ | LCK | P06239 | 1/20 | 0.77 |
| ▸ | FYN | P06241 | 1/20 | 0.77 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.77 |
| ▸ | HTR2A | P28223 | 1/20 | 0.77 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.77 |
| ▸ | KDM6B | O15054 | 1/20 | 0.53 |
| ▸ | PTPRC | P08575 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levodopa SCHEMBL17685857 | 1.00 | SLC7A5 (0.77) | SLC7A5USP2KDM4EALOX15RECQL | |
| Levodopa SCHEMBL17685886 | 0.91 | SLC7A5 (0.87) | SLC7A5USP2KDM4EALOX15RECQL | |
| Levodopa SCHEMBL29653523 | 0.91 | SLC7A5 (0.87) | SLC7A5USP2KDM4EALOX15RECQL | |
| Levodopa SCHEMBL9108304 | 0.91 | SLC7A5 (0.87) | SLC7A5USP2KDM4EALOX15RECQL | |
| Levodopa SCHEMBL31442655 | 0.91 | SLC7A5 (0.87) | SLC7A5USP2KDM4EALOX15RECQL | |
| Levodopa SCHEMBL13719874 | 0.91 | SLC7A5 (0.87) | SLC7A5USP2KDM4EALOX15RECQL | |
| Levodopa SCHEMBL28025802 | 0.90 | SLC7A5 (0.84) | SLC7A5USP2KDM4EALOX15RECQL | |
| Levodopa SCHEMBL27827872 | 0.90 | SLC7A5 (0.84) | SLC7A5USP2KDM4EALOX15RECQL | |
| Levodopa SCHEMBL28171274 | 0.90 | SLC7A5 (0.84) | SLC7A5USP2KDM4EALOX15RECQL | |
| Levodopa SCHEMBL11000382 | 0.88 | SLC7A5 (1.00) | SLC7A5USP2KDM4EALOX15RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765189-B2 | Organophosphorous and multivalent metal compound compositions and methods | Howmedica Osteonic Corp. (US) | 2014-07-01 | — | — | US | claimed |
| WO-2012158527-A2 | ORGANOPHOSPHOROUS & MULTIVALENT METAL COMPOUND COMPOSITIONS & METHODS | HOWMEDICA OSTEONICS (US) | 2012-11-22 | — | — | WO | claimed |
| US-20120288446-A1 | ORGANOPHOSPHOROUS & MULTIVALENT METAL COMPOUND COMPOSITIONS & METHODS | HOWMEDICA OSTEONICS CORP. | 2012-11-15 | — | — | US | claimed |
| EP-4186510-A1 | INTERMEDIATES AND PROCESS FOR PREPARING L-DOPA DIPHOSPHATE | AbbVie Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| EP-3569587-A1 | INTERMEDIATES AND PROCESS FOR PREPARING L-DOPA DIPHOSPHATE | AbbVie Inc. (US) | 2019-11-20 | — | — | EP | disclosed |
| US-8765189-B2 | Organophosphorous and multivalent metal compound compositions and methods | Howmedica Osteonic Corp. (US) | 2014-07-01 | — | — | US | disclosed |
| WO-2012158527-A2 | ORGANOPHOSPHOROUS & MULTIVALENT METAL COMPOUND COMPOSITIONS & METHODS | HOWMEDICA OSTEONICS (US) | 2012-11-22 | — | — | WO | disclosed |
| US-20120288446-A1 | ORGANOPHOSPHOROUS & MULTIVALENT METAL COMPOUND COMPOSITIONS & METHODS | HOWMEDICA OSTEONICS CORP. | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120288446-A1 | ORGANOPHOSPHOROUS & MULTIVALENT METAL COMPOUND COMPOSITIONS & METHODS | PHOSPHO1, PSPH, PTMS | SLC7A5 1983/4885USP2 3141/4885KDM4E 1924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.